GBT to Announce First Quarter 2021 Financial Results on Wednesday, May 5, 2021

Rhea-AI Summary

Global Blood Therapeutics (GBT) will release its Q1 2021 financial results on May 5, 2021, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. GBT is focused on developing treatments for sickle cell disease (SCD), including Oxbryta, its FDA-approved therapy. The company is also advancing its pipeline with inclacumab and GBT021601. Investors can access the conference call via the company's website.

Positive

• GBT's Oxbryta is the first FDA-approved treatment for SCD.
• Company is advancing a pipeline of treatments for SCD, which may drive future growth.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after U.S. financial markets close.

Management will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m. ET to provide a general business update and to discuss first quarter 2021 financial results. To participate in the conference call, please dial 877-407-3982 (domestic) or 201-493-6780 (international). A live audio webcast of the conference call can be accessed on GBT’s website at www.gbt.com under the Investors section. An archived audio webcast will be available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650.410.3258
simmergut@gbt.com

Courtney Roberts (investors)
650.351.7881
croberts@gbt.com

FAQ

When will Global Blood Therapeutics report its Q1 2021 financial results?

GBT will report its Q1 2021 financial results on May 5, 2021.

What time is the GBT conference call scheduled for?

The GBT conference call is scheduled for 4:30 p.m. ET on May 5, 2021.

How can I access the GBT conference call?

You can access the GBT conference call on the company's website under the Investors section.

What treatments does Global Blood Therapeutics focus on?

GBT focuses on treatments for sickle cell disease, including Oxbryta and its pipeline drugs inclacumab and GBT021601.